Crinetics Pharmaceuticals (CRNX) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free CRNX Stock Alerts $51.40 -0.51 (-0.98%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:59 AM | marketbeat.comJump Financial LLC Sells 20,393 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jump Financial LLC trimmed its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 43.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,083 shares of the company's stock after selling 20,393 sharMay 17 at 6:35 PM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Down 5.9% in AprilCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 4,910,000 shares, a decline of 5.9% from the April 15th total of 5,220,000 shares. Based on an average daily volume of 827,000 shares, the short-interest ratio is presently 5.9 days.May 16, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High at $51.60Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High at $51.60May 16, 2024 | americanbankingnews.comCrinetics Pharmaceuticals' (CRNX) "Overweight" Rating Reaffirmed at Cantor FitzgeraldMay 15, 2024 | insidertrades.comStephen F. Betz Sells 3,000 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockMay 15, 2024 | marketbeat.comVictory Capital Management Inc. Buys 139,117 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Victory Capital Management Inc. boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 309.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 184,107 shares of the company's stocMay 14, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Stephen F. Betz Sells 3,000 SharesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 3,000 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $49.43, for a total value of $148,290.00. Following the transaction, the insider now owns 89,643 shares of the company's stock, valued at $4,431,053.49. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.May 14, 2024 | markets.businessinsider.com18 Analysts Have This To Say About Crinetics PharmaceuticalsMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)May 14, 2024 | marketbeat.comCrinetics Pharmaceuticals' (CRNX) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $65.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Tuesday.May 13, 2024 | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call TranscriptMay 13, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Earns "Market Outperform" Rating from JMP SecuritiesMay 13, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)May 12, 2024 | insidertrades.comRichard Scott Struthers Sells 107,448 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockMay 11, 2024 | finance.yahoo.comInvestors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three yearsMay 11, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). The business had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.20 million. Crinetics Pharmaceuticals had a negative return on equity of 52.93% and a negative net margin of 4,223.27%. The business's revenue was down 76.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.85) EPS.May 10, 2024 | markets.businessinsider.comBuy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising Clinical DataMay 10, 2024 | marketbeat.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells 107,448 Shares of StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 107,448 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $49.40, for a total transaction of $5,307,931.20. Following the transaction, the chief executive officer now directly owns 257,485 shares in the company, valued at approximately $12,719,759. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.May 10, 2024 | marketbeat.comCrinetics Pharmaceuticals' (CRNX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Crinetics Pharmaceuticals in a report on Friday.May 10, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial ResultsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals on Strong Drug Pipeline and Market PotentialMay 10, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | investorplace.comCRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comPromising Outlook for Crinetics Pharmaceuticals Ahead of CRN04894 Phase 2 Data ReleaseMay 8, 2024 | finance.yahoo.comCrinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024May 7, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $97.00Piper Sandler boosted their price target on shares of Crinetics Pharmaceuticals from $56.00 to $97.00 and gave the company an "overweight" rating in a report on Tuesday.May 6, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Holdings Boosted by Lisanti Capital Growth LLCLisanti Capital Growth LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 100.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,245 shares of the company's stock afterMay 3, 2024 | marketbeat.comCrinetics Pharmaceuticals (CRNX) Set to Announce Earnings on ThursdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | globenewswire.comCrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024April 29, 2024 | marketbeat.com101,196 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Bought by abrdn plcabrdn plc bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 101,196 shares of the company's stock, valued at approximately $3,60April 23, 2024 | marketbeat.comJennison Associates LLC Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jennison Associates LLC lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 77.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,547,683 shares of the comApril 18, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of StockApril 17, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $639,256.25 in StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 14,375 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $44.47, for a total value of $639,256.25. Following the completion of the sale, the insider now owns 27,786 shares in the company, valued at $1,235,643.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.April 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Up 5.1%Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Up 5.1%April 9, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in StockApril 5, 2024 | marketbeat.comVanguard Group Inc. Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Vanguard Group Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 24.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,407,035 shares of the company's stock aApril 3, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume IncreaseCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Strong Trading VolumeApril 3, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 SharesApril 3, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from AnalystsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eleven haveApril 2, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Significant Growth in Short InterestCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 5,010,000 shares, an increase of 5.7% from the February 29th total of 4,740,000 shares. Based on an average daily volume of 745,500 shares, the days-to-cover ratio is currently 6.7 days.April 2, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Sells $811,650.00 in StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Stephanie Okey sold 17,500 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $46.38, for a total value of $811,650.00. Following the completion of the transaction, the director now owns 6,000 shares of the company's stock, valued at $278,280. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.April 1, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High at $48.00Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High at $48.00March 28, 2024 | investing.comCrinetics Pharmaceuticals COO sells shares worth over $1.4 millionMarch 28, 2024 | insidermonkey.comInsiders Are Dumping These 5 Healthcare Stocks Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. CRNX Media Mentions By Week CRNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.660.42▲Average Medical News Sentiment CRNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼144▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Insmed News Today HUTCHMED News Today Axsome Therapeutics News Today Perrigo News Today Alkermes News Today Prestige Consumer Healthcare News Today Nuvalent News Today Ultragenyx Pharmaceutical News Today Alpine Immune Sciences News Today Madrigal Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
